Affiliation:
1. Department of Urology, Henan Traditional Chinese Medicine Hospital, Zhengzhou, Henan, 450003, China
Abstract
Background:
Emerging studies have indicated that circular RNAs (circRNAs) play important
roles in the development of many tumors. CircRNA-scavenger receptor class B member 1
(Circ-SCARB1) was consistently reported as an elevated circRNA in RCC tissues. This study focused
on examining the biological function and molecular mechanism of circSCARB1 in RCC progression.
Methods:
Expressions of Circ-SCARB1, microRNA (miR)-510-5p, and syndecan 3 (SDC3) were
detected using a quantitative real-time polymerase chain reaction (RT-PCR) and/or western blot.
Cell proliferation and apoptosis were measured by 3-(4, 5)-dimethylthiahiazo (-z-y1)-3, 5-diphenytetrazoliumromide
and flow cytometry, respectively. Cell migration and invasion were measured
using Transwell assays. The interaction between miR-510-5p and Circ-SCARB1 or SDC3 was
verified using dual-luciferase reporter assays.
Results:
Circ-SCARB1 was elevated in 30 pairs of RCC tissues and multiple RCC cell lines.
Knockdown of Circ-SCARB1 inhibited cell proliferation, migration, and invasion while inducing
cell apoptosis. MiR-510-5p was confirmed to be a target of Circ-SCARB1; inhibition of cell progression
by silencing Circ-SCARB1 was mediated by a direct interaction between Circ-SCARB1
and miR-510-5p. SDC3 was verified to be a gene target of miR-510-5p; transfection of miR-510-5p
mimic not only suppressed the expression of SDC3 but also the cell proliferation and an SDC3 cotransfection
partially restored cell proliferation. Additionally, the genetic knockdown of Circ-
SCARB1 reduced the expression SDC3, and the addition of anti-miR-510-5p could partially reelevate
SDC3 expression.
Conclusion:
Circ-SCARB1 promotes RCC progression via sequestering miR-510-5p and indirectly
up-regulating SDC3 expression. This provides a novel perspective for the pathogenesis of RCC and
potential therapeutic targets for the treatment of RCC.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Drug Discovery,Pharmacology,Oncology
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献